Establish their baseline TTMV-HPV DNA Score to reassure patients their disease is being effectively managed
Before starting treatment, know their TTMV-HPV DNA Score and tumor HPV-genotype
Use the NavDx blood test pretreatment to confirm HPV association and establish a baseline TTMV-HPV DNA Score:
- Confirm the tumor HPV genotype, to help prognosticate and plan treatment based on your patient's risk profile4
- In a recent study, TTMV-HPV DNA detection strongly correlated with HPV tumor status as established by rigorous HPV genotyping for patients with active HNSCCs8
- TTMV-HPV DNA was detected in 92% of HPV positive OPSCC patients, and in none of the HPV negative OPSCC patients8
- In a recent study, TTMV-HPV DNA detection strongly correlated with HPV tumor status as established by rigorous HPV genotyping for patients with active HNSCCs8
- Establish a baseline circulating TTMV-HPV DNA Score to measure and compare changes during treatment and surveillance4
-
Aid in the identification of patients whose therapy should not be de-escalated
- 15% to 25% of OPSCC patients test positive for p16 even though their cancer is actually HPV negative9
Use the NavDx test at least 7 days after any biopsy procedure, and prior to initiating treatment
Identifying their tumor HPV genotype and baseline TTMV Score from de-escalation therapy
Order a NavDx Test
References
1. Ferrandino RN, Chen S, Kappauf C, et al. Performance of liquid biopsy for diagnosis and surveillance of human papillomavirus–associated oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg. doi:10.1001/jamaoto.2023.1937. 2. Hanna GJ, Roof SA, Jabalee J, et al. Negative predictive value of circulating tumor tissue modified viral (TTMV)-HPV DNA for HPV-driven oropharyngeal cancer surveillance. Clin Cancer Res 2023. doi: 10.1158/1078-0432.CCR-23-1478. 3. Berger BM, Hanna GJ et al. Detection of Occult Recurrence Using Circulating Tumor Tissue Modified Viral HPV DNA among Patients Treated for HPV-Driven Oropharyngeal Carcinoma. Clin Cancer Res 2022;28(19):4292–4301. 4. Chera BS, Kumar S, Shen C, et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. J Clin Oncol. Apr 1 2020;38(10):1050-1058. doi:10.1200/JCO.19.02444. 5. Lin MG, Zhu A, Read PW, et al. Novel HPV associated oropharyngeal squamous cell carcinoma surveillance DNA assay cost analysis. Laryngoscope. Nov 2023; 133:306-312. 6. Chera BS, Kumar S, Beaty BT, et al. Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer. Clin Cancer Res. Aug 1 2019;25(15):4682-4690. doi:10.1158/1078-0432.CCR-19-0211 7. International Agency for Research on Cancer. Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 90. Geneva, Switzerland: World Health Organization, 2007. 8. Mijares K, Ferrandino R, Chai R, et al. Circulating Tumor HPV DNA in Patients With Heand and Neck Carcinoma: Correlation With HPV Genotyping. Am J Surg Pathol. 2023:00:000-000. 9. Mirghani H, Moreau F, Lefevre M, et al. Human papillomavirus type 16 oropharyngeal cancers in lymph nodes as a marker of metastases. Arch Otolaryngol Head Neck Surg. Sep 2011;137(9):910-4. doi:10.1001/archoto.2011.141. 10. Gupta T, Master Z, Kannan S, et al. Diagnostic perfor¬mance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging38, 2083–2095(2011). doi.org/10.1007/s00259-011-1893-y. 11. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. Jul 1 2010;363(1):24-35. doi:10.1056/NEJMoa0912217 12. Fakhry C, Zhang Q, Nguyen-Tan PF, et al. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol. Oct 20 2014;32(30):3365-73. doi:10.1200/JCO.2014.55.1937 13. Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. Jan 5 2019;393(10166):40-50. doi:10.1016/S0140-6736(18)32779-X. 14. Elaldi R, Roussel LM, Gal J, et al. Correlations between long-term quality of life and patient needs and concerns following head and neck cancer treatment and the impact of psychological distress. A multicentric cross-sectional study. Eur Arch Otorhinolaryngol. Jul 2021;278(7):2437-2445. doi:10.1007/s00405-020-06326-8. 15. Kuhs KA, Brenner CJ, Holsinger CF, et al. Circulating tumor HPV DNA for surveillance of HPV-positive oropharyngeal squamous cell carcinoma, JAMA Oncol. doi:10.1001/jamaoncol.2023.4042. Published online October 12, 2023.